Research Now, an online sampling and data collection company that collects visitors’ digital data by tracking their social networks and referring sites, has just launched a Gastrointestinal Panel designed to provide users with a more comprehensive resource on the latest practices and treatments in gastrointestinal medicine, as well as public opinions and sentiments from patients diagnosed with GI problems.
Through this new panel, researchers will gain access to an audience of hundreds of thousands of intensively-profiled panelists, diagnosed with either Crohn’s disease, ulcerative colitis, gastroesophageal reflux disease (GERD), anemia, constipation, Hepatitis B, Hepatitis C and irritable bowel syndrome (IBS). To make the panel experience more immersive and educational, the company also includes access to caregivers and in-demand healthcare professionals, such as gastroenterologists, nurses, hepatologists, pharmacists and radiologists.
Senior Vice President of Global Healthcare Vincent DeRobertis commented, “As a leading research provider in the healthcare industry, Research Now understands that direct access to patients, caregivers and physicians is needed in order to gain deeper insights into medical conditions. With our Gastrointestinal Panel, we offer access to quality, primary data from individuals suffering from and treating gastrointestinal disorders. This unique, new resource enables researchers to explore the attitudes and experiences of those directly affected, and complements our existing specialty healthcare panels in the marketplace.”
The new Gastrointestinal Panel marks Research Now’s 6th market research panel that revolves around key areas of healthcare and medical treatment. The company’s 5 other deeply-profiled panels cover the following health concerns: diabetes, arthritis, autoimmune diseases, women’s health and mental health.
In other IBD-related developments, a new study published in the journal Clinical Gastroenterology and Hepatology reports the safety and efficacy of reintroducing Infliximab therapy for patients with Crohn’s disease or ulcerative colitis. They found reintroducing infliximab therapy yielded positive results for 84.5% of patients ( at week 14 of treatment) and 70% of patients (within one year).
Andres J. Yarur, MD, and Maria T. Abreu, MD, both from the University of Miami Miller School of Medicine, and not authors of the study noted, “The first important message in this study was that restarting infliximab after a drug holiday is feasible. Incorporation of testing drug levels and [antibodies to infliximab] appears useful and allows a more personalized approach to their care. With the recent approval of vedolizumab (Entyvio, Takeda Pharmaceuticals), we expect that patients who have a lack of response in spite of adequate through levels of anti-TNF will benefit from a change in mechanism of biologic action.”
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?